anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Use of an extract derived from the fruits, the leaves, the bark or the roots of Morinda citrifolia L. for the manufacture of a medicament for the treatment of a mammal suffering from tinnitus. The extract may be a liquid present in the medicament in an amount such as to give a daily dosage of 0.1-2 ml, or 0.2-1 ml, e.g. 0.4-0.7 ml, per kg body weight of the patient. The extract also may be a solid present in the medicament in an amount such as to give a daily dosage of 5-200 mg, or 10-100 mg, e.g. 20-70 mg, per kg body weight of the patient. Optionally, the medicament also may comprise lycopene, vitamine C, coenzyme Q10 and an extract from the leaves of Ginkgo biloba. The medicament may be given e.g. by oral, rectal, transdermal or inhalation administration.
You're going to undergo a procedure called a reverse shoulder replacement and I'm sure Dr. Gilotra already went over the procedure with you but I will again briefly. Before the hardware is put in, there is a tendon in your shoulder that has to be "released". It's released because the doctor has to move it out of the way to get to your shoulder joint. Now when the hardware has been implanted and the surgery is complete, the doctor now has two options. He can decide to repair this tendon or not. The thing is due to the hardware that is implanted, your shoulder doesn't really need this tendon anymore to help it move. So, there are some doctors in the country who choose to repair the tendon and there are some doctors who choose to just let it be. Patients have done great with either or.

We are performing this nationwide study to see if one option (between repairing this tendon or leaving it) is slightly better than the other. There is a chance that repairing the tendon can decrease the risk of dislocations in the future and also help you move your arm better. There is a chance that this repair doesn't matter at all. If we figure out whether to repair or not to repair this tendon, we will be able to better define complications, potentially decrease surgery time, and improve how well patients perform daily activities.

We randomize you to the repair on don't repair group, almost like flipping a coin. With me, you'll be answering simple questions that will track your functionality over time.
The invention relates to a dental alloy with a high gold content that is devoid of palladium and copper. To achieve a high mechanical stability, the dental alloy consists of between 75 and 95 wt. % Au, between 5 and 20 wt. %  Pt, between 0.5 and 3.5 wt. % Zn and/or Sn and/or In, between 0.1 and 0.8 wt.  % of an element of a group I, in addition to a single particle refiner of a group II. The weight fraction of the element of group I is between 2 and 6 times that of the single particle refiner of group II, and one element of the group I is represented by Nb or Ta or Ti or V and the particle refiner of group II is represented by Ir or Rh.
9,10-Dihydroxy-1,4-dihydroanthracene-1,4-dione compound (I), as an agent for tumor suppression and inhibition of tumor angiogenesis, is new. 9,10-Dihydroxy-1,4-dihydroanthracene-1,4-dione compound of formula (I), as an agent for tumor suppression and inhibition of tumor angiogenesis, is new. Independent claims are also included for: (1) a pharmaceutical composition (A) comprising (I), carriers and diluents; and (2) a method for preparing (A) comprising mixing (I) with one or more carriers and diluents and bringing the mixture into a suitable administration form. [Image] ACTIVITY : Cytostatic. MECHANISM OF ACTION : Tumor angiogenesis inhibitor; Protein kinase 2 inhibitor; Protein kinase D inhibitor. The protein kinase D inhibitory activity of (I) was tested using HeLa cells in a biological assay. The results showed that the median inhibitory concentration of (I) is 39.69 mu M.
STUDY OBJECTIVE: Newer regional anesthesia techniques and minimally invasive surgeries have yielded decreased postoperative pain scores, potentially leading to decreased need for perioperative epidural analgesia. Limited literature is available on trends in usage rates of epidurals. The objective of this study was to identify trends in perioperative epidural analgesia rates among multiple fields of surgery.
METHODS: All patients undergoing general, thoracic, urologic, plastic, vascular, orthopedic, or gynecological surgery in 2014-2020 were included from the National Surgical Quality Improvement Program database of over 700 hospitals in the U.S. and 11 different countries. Annual trends in epidural analgesia for all surgeries and each surgical specialty were assessed by mixed effects multivariable logistic regression. The odds ratios (OR) and 99 % confidence intervals (CI) were reported.
RESULTS: There were 3,111,435 patients from 2014 to 2020 that were included in the final analysis, in which 107,209 (3.4 %) received perioperative epidural analgesia. Among all surgeries combined, epidural use throughout the study period decreased (OR 0.98 per year, 99 % CI 0.97-0.98, P < 0.001). When only analyzing the surgeries with the top 5 most frequent epidural use per specialty, there was no statistically significant trend in epidural utilization (OR 0.99 per year, 99 % CI 0.99-1.00, P = 0.09). However, there was an increasing trend in epidural utilization in general surgery (OR 1.05 per year, 99 % CI 1.03-1.07, P < 0.001) and vascular surgery (OR 1.08 per year, 99 % CI 1.05-1.10, P < 0.001).
CONCLUSION: Rates of perioperative epidural analgesia use has decreased in recent years overall, however, among surgeries within the general surgery and vascular surgery specialty, utilization has increased for procedures that have the highest rates of usage.
The invention relates to a pure natural and non-polluting antihypertensive tea with multiple functions such as hypertension reducing, blood fat reducing, blood sugar reducing, cholesterol reducing, diabetes preventing and treating, and the like. The tea is an internal medicine. The tea is prepared from smallage, avicennia pricklyash root, branch camellia, corn stigma, pine needle, tea leaf, and immature chinese holly leaf according to a certain weight (g) ratio. The tea has rapid and substantial effects in treating hypertension and cerebral arteriosclerosis, reducing blood fat, reducing blood sugar, reducing cholesterol, treating obesity, preventing and treating diabetes, resisting aging, resisting cancer, and preventing cancer. With the tea, patient suffering are completely solved, and an effective health-care function is provided for health populations. The tea is safe and reliable, and causes no toxic or side effect.
Compositions and methods are provided for the modulation of expression of the gene encoding .beta.-amyloid in both the normal and mutant forms. Oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from the .beta.-amyloid precursor (.beta.APP) gene encoding .beta.-amyloid, having nucleotide units sufficient in identity and number to effect such specific hybridization. Oligonucleotides specifically hybridizable with a translation initiation site or with the codon-717 mutation of .beta.APP are provided. Such oligonucleotides can be used for diagnostics as well as for research purposes. Methods are also disclosed for modulating .beta.-amyloid expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of the mutant .beta.APP gene. Methods for diagnosis, detection and treatment of conditions arising from the mutation of the .beta.APP gene are also disclosed.
Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
The invention describes an anonymous health care and record system. Described herein in is to ensure anonymity of a health record via a cipher technology (anonymous proving system) during treatment of payment claims relative to an insurer and a drug store. A patient receives a patient token from the insurer, and entrusts the token to a health care provider. The entrusted token is processed to be an anonymous token identifying a health care provider and the provided medical service, not including information directly identifying a patient. The anonymous token comprises data used by the insurer to ensure effectiveness of the token. With respective to the prescription, the anonymous token can be generated as an endorsement of the patient (for example, a printing bar code) and a token without an endorsement sent to the drugstore. The data with the endorsement and the token without the endorsement are combined into an anonymous combination token in the drugstore, and the anonymous combination token is sent to the insurer for payment.
BACKGROUND: Liver stiffness (LS) measurement with two-dimensional shear wave elastography (2D-SWE) correlates with the degree of liver fibrosis and thus indirectly reflects liver function reserve. The size of the spleen increases due to tissue proliferation, fibrosis, and portal vein congestion, which can indirectly reflect the situation of liver fibrosis/cirrhosis. It was reported that the size of the spleen was related to posthepatectomy liver failure (PHLF). So far, there has been no study combining 2D-SWE measurements of LS with spleen size to predict PHLF. This prospective study aimed to investigate the utility of 2D-SWE assessing LS and spleen area (SPA) for the prediction of PHLF in hepatocellular carcinoma (HCC) patients and to develop a risk prediction model.
AIM: To investigate the utility of 2D-SWE assessing LS and SPA for the prediction of PHLF in HCC patients and to develop a risk prediction model.
METHODS: This was a multicenter observational study prospectively analyzing patients who underwent hepatectomy from October 2020 to March 2022. Within 1 wk before partial hepatectomy, ultrasound examination was performed to measure LS and SPA, and blood was drawn to evaluate the patient's liver function and other conditions. Least absolute shrinkage and selection operator logistic regression and multivariate logistic regression analysis was applied to identify independent predictors of PHLF and develop a nomogram. Nomogram performance was validated further. The diagnostic performance of the nomogram was evaluated with receiver operating characteristic curve compared with the conventional models, including the model for end-stage liver disease (MELD) score and the albumin-bilirubin (ALBI) score.
RESULTS: A total of 562 HCC patients undergoing hepatectomy (500 in the training cohort and 62 in the validation cohort) were enrolled in this study. The independent predictors of PHLF were LS, SPA, range of resection, blood loss, international normalized ratio, and total bilirubin. Better diagnostic performance of the nomogram was obtained in the training [area under receiver operating characteristic curve (AUC): 0.833; 95% confidence interval (95%CI): 0.792-0.873; sensitivity: 83.1%; specificity: 73.5%] and validation (AUC: 0.802; 95%CI: 0.684-0.920; sensitivity: 95.5%; specificity: 52.5%) cohorts compared with the MELD score and the ALBI score.
CONCLUSION: This PHLF nomogram, mainly based on LS by 2D-SWE and SPA, was useful in predicting PHLF in HCC patients and presented better than MELD score and ALBI score.
Caesarean section (C-section) is the most performed major surgery worldwide. About 15% of births are delivered through C-section in Rwanda. The post-caesarean surgical section is one of the most frequent complications that follow a C-section. The purpose of this systematic review and meta-analysis is to estimate the pooled prevalence of surgical site infections following caesarean section deliveries in Rwanda. A comprehensive search was conducted across PubMed/MEDLINE, Google Scholar, DOAJ, AJOL and the Cochrane Library to identify primary studies on post-caesarean surgical site infections in Rwanda. Studies meeting predetermined criteria were included, and their quality was assessed using the JBI Critical Appraisal Tools. Heterogeneity was evaluated using I2 statistics, while publication bias was examined via funnel plots and statistical tests. Pooled prevalence was calculated using Jamovi 2.3.28 software, with subgroup analysis conducted to identify sources of heterogeneity. Statistical significance was set at p < 0.05. From 139 articles initially searched from the databases, only 17 studies with 8, 082 individuals were finally included in the systematic review and meta-analysis. Using the random-effects model, the pooled estimate of post C-section SSIs prevalence in Rwanda was 6.85% (95% CI 5.2, 8.5). Subgroup analysis based on publication year, sample size, hospital and study design showed no much difference in SSI prevalence. The current systematic review and meta-analysis indicates that post-caesarean surgical site infections are significant in Rwanda. A collaborative effort is required to lower post-C-section SSIs and provide the best surgical care in the country.
Hearing loss, also termed as hearing impairment, is an ailment where hearing is impaired partially or fully. About one in eight people suffer from hearing loss worldwide. The main aim of this current systematic review was to analyze the clinical effectiveness of cochlear implant (CI) surgery in pediatric and adult patients. The current study was carried out as a systematic review, following the PRISMA guidelines. We systematically searched PubMed, MEDLINE, EMBASE, and Google Scholar databases to identify eligible articles on the clinical effectiveness of CI surgery with the appropriate key terms (MeSH). This review included 73 studies which met the inclusion criteria. The studies included in unilateral CI in adults showed significant improvement in terms of perceptive abilities. Bilateral CI studies with respect to unilateral CI provide benefits in hearing in quiet conditions and sound localization. In the performance of post CI outcomes in patients, the age is not a determinant factor. CI is an effective aid in communication and speech perception for a majority of people with mild to severe hearing loss. Further studies are needed with large databases, patient registries for long term follow up details, higher quality reporting, and longer duration to develop stronger evidence.
The present inventors constructed mammalian cell-infecting virus vectors encoding epitope-linked- beta 2m and succeeded in large-scale expression of epitope-linked- beta 2m in mammalian cells. The present invention provides mammalian cell-infecting virus vectors that encode epitope-linked- beta 2m microglobulin ( beta 2m) and uses thereof. Furthermore, the present invention provides a method for producing an MHC class I/peptide complex using the vector. In particular, a tetramerized MHC class I/peptide complex is useful in detecting epitope-specific CD8-positive T cells. Moreover, the present invention provides cells introduced with the vector. Target cells added with epitope-linked- beta 2m produced by the vector of the present invention are also provided. These cells were recognized by antigen-specific cytotoxic T lymphocytes (CTL) . The vectors of this invention and polypeptides obtained via the expression of the vectors are useful in immunotherapy for infections and cancers, and in the detection and quantification of antigen-specific CTL.
Systems and method are disclosed for determining a concentration of an analyte in a fluid (e.g., blood). The system can draw blood from a patient and deliver the blood to a sample cell. A particular component of the fluid (e.g., plasma) may be separated and/or positioned such that the concentration of the analyte is measured in the particular component of the fluid (e.g., plasma). The sample cell can include a sample container that has two window pieces. The system can have a fluid passage having a tip configured to mate with a multi-lumen catheter without leaking. The multi-lumen catheter can have proximal and distal ports. A fluid pressure system can be configured to periodically draw fluid from vasculature through a proximal intravascular opening and the proximal port while maintaining a low pressure and/or flow rate to thereby reduce risk of reversing the fluid flow in a vessel and drawing infusates upstream into another intravascular opening.
All patients underwent a medical evaluation that included physical examination and routine laboratory studies before and after transcranial direct current stimulation (tDCS) treatment. Patients were randomly allocated to real group , sham group or control group. A threshold of 3 points on the Hamilton Depression scale has been specified by the National Institute for Health and Care Excellence to determine a clinically meaningful difference between active pharmacotherapy and placebo. We plan to enroll minimum total sample size of 37 participants in real, sham or control group respectively according to the Power and Sample Size program. The decision to enroll a patient was always made prior to randomization. The tDCS administrators had access to the randomization list. They had minimal contact with the patients, and no role in assessing depression. Each patient would be treated for continuous 14 days by tDCS in real and sham group. The control group was evaluated by clinical symptom scale, behavioral evaluation before and after 14 days.

Before the tDCS treatment, depression symptom of each participant was assessed by the Hamilton Depression Scale and the Beck Depression Self-Rating Scale. The anhedonia severity was evaluated by The Temporal Experience of Pleasure Scale, the Self-Report Apathy Evaluation Scale, Dimensional Anhedonia Rating Scale, the Motivation and Pleasure Scale.The neuroimaging data was collected using event-related potentials during monetary incentive delay task. After the last treatment, the same scales and neuroimaging scan were used again to assess the treatment effect of the tDCS and the underlying brain mechanism. Each participant was interviewed in detail about the adverse event of the tDCS intervention during the past 14 days.Every participant should take part in the study in voluntary and sign an informed consent form before the study.
The invention discloses an acne-removing composition and application thereof in cosmetics. The acne-removing composition comprises a filtrate of a fermentation product of tectorial membrane yeast, fruit acid, antibacterial peptide, nano-encapsulated azelaic acid and glycyrrhetinic acid monoglucuronide. The mass percentage of the filtrate of the fermentation product of the tectorial membrane yeast in the acne-removing composition is 50-80%. The fruit acid is more than one of malic acid, glycolic acid, lactic acid, tartaric acid, citric acid or mandelic acid, and the mass percent of the fruit acid in the composition is 5-20%. The acne-removing composition can be applied to cosmetics. The acne-removing composition disclosed by the invention achieves the effects of quickly inhibiting inflammation, sterilizing, controlling oil and removing cutin through the synergistic effect of the five effective components, comprehensively and effectively suppresses acne, has a safe and efficient acne-removing effect, is composed of natural active substances, and has no side effect.
INTRODUCTION: Bruton's tyrosine kinase (BTK) and interleukin (IL)-2 Inducible T-cell Kinase (ITK) inhibitors have anti-inflammatory properties. We investigated the therapeutic effect of ibrutinib, an orally bioavailable BTK/ITK inhibitor, in a mouse model of Graves' orbitopathy (GO).
METHODS: Genetic immunization was performed through intramuscular administration of the recombinant plasmid, pCMV6-hTSHR cDNA, to 8-week-old female BALB/c mice. Serum levels of T3, T4, and thyroid-stimulating hormone receptor (TSHR) antibodies (TRAbs) were quantified using enzyme-linked immunosorbent assay. Histopathological changes in orbital tissues were examined using immunohistochemistry (IHC) staining for TSHR and various inflammatory markers. Following successful genetic immunization, ibrutinib was orally administered daily for 2 weeks in the GO model mice. After treatment, the mRNA and protein expression levels of BTK, ITK, IL-1β, and IL-6 in orbital tissues were evaluated using real-time PCR and Western blotting.
RESULTS: In total, 20 mice were sacrificed to confirm successful genetic immunization. The GO mouse group exhibited significantly increased serum T3, T4, and TRAb levels. IHC revealed increased expression of TSHR, IL-1β, IL-6, transforming growth factor-β1, interferon-γ, CD40, CD4, BTK, and ITK in the GO mouse model. The orbital inflammation was significantly attenuated in ibrutinib-treated mice. The mRNA and protein expression levels of BTK, ITK, IL-1β, and IL-6 in orbital tissue were lower in ibrutinib-treated GO mouse group compared to the phosphate-buffered saline-treated GO mouse group.
CONCLUSION: The GO mouse model demonstrated enhanced BTK and ITK expression. Ibrutinib, a BTK/ITK inhibitor, suppressed the inflammatory cytokine production. These findings highlight the potential involvement of BTK/ITK in the inflammatory pathogenesis of GO, suggesting its role as a novel therapeutic target.
The extensive use of polymers in the medical field has facilitated the development of various devices and implants, contributing to the restoration of organ function. However, despite their advantages such as biocompatibility and robustness, these materials often face challenges like bacterial contamination and subsequent inflammation, leading to implant-associated infections (IAI). Integrating implants effectively is crucial to prevent bacterial colonization and reduce inflammatory responses. To overcome these major issues, surface chemical modifications have been extensively explored. Indeed, click chemistry, and particularly, copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction has emerged as a promising approach for surface functionalization without affecting material bulk properties. Curcumin, known for its diverse biological activities, suffers from low solubility and stability. To enhance its bioavailability, bioconjugation strategy has garnered attention in recent years. This study represents pioneering work in immobilizing curcumin derivative onto polyethylene terephthalate (PET) surfaces, aiming to combat bacterial adhesion, inflammation and coagulation. Before curcumin derivative bioconjugation, a fluorophore, dansyl derivative, was employed in order to monitor and determine the efficiency of the proposed methodology. Previous surface chemical modifications were required for the immobilization of both dansyl and curcumin derivatives. Ultraviolet-Visible (UV-Vis) demonstrated the amidation functionalization of PET surface. Other surface characterization techniques including X-ray Photoelectron Spectroscopy (XPS), Attenuated Total Reflectance Fourier Transformed Infrared (ATR-FTIR), Scanning Electron Microscopy (SEM) and contact angle, among others, confirmed also the conjugation of both dansyl and curcumin derivatives. On the other hand, different biological assays corroborated that curcumin derivative immobilized PET surfaces do not exhibit cytotoxicity effect. Additionally, corresponding inflammation test were performed, indicating that these polymeric surfaces do not produce inflammation and, when curcumin derivative is immobilized, they decrease the inflammation marker level (IL-6). Moreover, the bacterial growth of both Gram positive and Gram negative bacteria were measured, demonstrating that the immobilization of curcumin derivative on PET provided antibacterial properties to the material. Finally, hemolysis rate analysis and whole blood clotting assay demonstrated the antithrombogenic effect of PET-Cur surfaces as well as no hemolysis concern in the fabricated functional surfaces.